Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

By M. Ahmadzadeh, L. Johnson, B. Heemskerk, J. Wunderlich, M. Dudley, D. White, S. Rosenberg. Blood, 2009

1,711 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/cf48201cd1354ab6e0f9a388eb0f05e6941ce0d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Overcoming T cell exhaustion in infection and cancer (2015, background): “Recent clinical trials have shown that blocking the PD-1:PD-L1 pathway enhances immunity in several cancer types including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and others, leading to objective responses in a number of patients [16, 21–23, 25–32].”
T Cell Dysfunction in Cancer (2018, background): “induces a sustained expression of PD-1, which characterizes—and possibly drives—T cell dysfunction (Ahmadzadeh et al., 2009; Baitsch et al., 2011; Wherry, 2011).”
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors (2013, background): “Mechanisms regulating immune activation in cancer progression have been extensively investigated (4-16).”
Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy (2018, positive): “…CD8+ T cells in T cell high tumors is in keeping with the more antigen-experienced tumorreactive T cell populations described in other tumor types (Ahmadzadeh et al., 2009; Fourcade et al., 2010) and yet is only revealed in PDA when using these clonal tumor cell lines with dichotomous immune…”
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade (2018, neutral): “5 (2D1), -CD56 PE (CMSSB), - CD3 APC-eFluor780 (SK7), -Lag-3 FITC (3DS223H), -TIGIT PE (MBSA43), -2B4 FITC (eBioDM244), -CD137 FITC (4B4), -IL-2 PE (MQ1-17H12), -TNF-α APC (MAb11), - CD26 FITC (2A6), -CXCR5 Biotin (MU5UBEE), -ICOS FITC (ISA-3), -CD38 APC (HIT2), -Eomes eFluor660 (WD1928), -T-bet PE ”
Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “Co-stimulation is mediated by a tightly controlled interplay of stimulatory and inhibitory receptor and ligand pairs [19, 20].”
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “TILs express high levels of PD-1 inmany settings (27, 29, 290), and PD-L1 is expressed on many types of cancer cells as well as myeloid cells in the tumor microenvironment in response to inflammatory signals (291, 292).”
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. (2011, background): “Tumor-infiltrating T cells are functionally deficient (20, 23, 24, 34), which is likely coresponsible for the limited efficacy of immunotherapy.”